Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031).

Vera J SumanLili Du Tanya L Hoskin Meenakshi Anurag Cynthia X Ma Isabelle Bedrosian Kelly K Hunt Matthew J Ellis William Fraser Symmans

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

This exploratory analysis of Z1031 data demonstrated a higher rate of pharmacodynamic suppression of proliferation and longer EFS in high SET2,3 disease relative to low SET2,3 disease. The ypStage 0/I rate and PEPI = 0 rate were similar with respect to SET2,3.

Keyphrases

rectal cancer
lymph node
signaling pathway
squamous cell carcinoma
stem cells
locally advanced
electronic health record
radiation therapy
young adults
mesenchymal stem cells
replacement therapy
preterm birth
artificial intelligence